Senseonics wins CE Mark for Eversense XL glucose monitor

This article was originally published here

Senseonics (NYSE:SENS) said yesterday that it won CE Mark approval in the European Union for its Eversense XL continuous glucose monitor.

The Eversense XL includes a glucose sensor designed to be implanted for 180 days and a removable smart transmitter that links with a mobile app for real-time glucose monitoring. Germantown, Md.-based Senseonics touts the sensor as the world’s longest lasting compared with others that require weekly insertions.

Get the full story at our sister site, Drug Delivery Business News.

The post Senseonics wins CE Mark for Eversense XL glucose monitor appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply